EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) will be discussing 1Q21 financial results with the investment community.on 5th November 2020 at 8:30 AM eastern time.
Those interested in listening to the conference call live via the Internet can visit eyepointpharma.com
Earnings Expectation
EyePoint Pharmaceuticals, Inc. is set to announce first quarter earning results on Thursday 5th November 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, EYPT to report 1Q21 loss of $ 0.03 per share. For the full year, analysts anticipate top line of $ 32.14 million, while looking forward to loss of $ 0.33 per share bottom line.
EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States and Europe. It provides ILUVIEN for the treatment of diabetic macular edema; YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis (NIPU) that is in the Phase III clinical trials; and Retisert (fluocinolone acetonide intravitreal implant), a sustained-release implant for the treatment of posterior segment uveitis. The company also offers DEXYCU (dexamethasone intraocular suspension), an intraocular product for the treatment of postoperative ocular inflammation; and Vitrasert (ganciclovir), a sustained release implant for the treatment of cytomegalovirus retinitis.
